SWITCH study of efficacy and safety of sorafenib/sunitinib vs. sunitinib/sorafenib in the treatment of mRCC

According to results of the SWITCH, a randomised sequential open-label study, that evaluated efficacy and safety of sorafenib/sunitinib vs. sunitinib/sorafenib in the treatment of metastatic renal cell cancer, there is no difference whether patients first start on sorafenib and then switch to sunitinib upon progression or vice versa. Progression-free survival and overall survival outcomes across the two sequences were similar, as reported by lead investigator Dr Maurice-Stephan Michel of the University Medical Center Mannheim and the University of Heidelberg in Germany. The findings were reported at 2014 Genitourinary Cancer Symposium in San Francisco. Read more here.